在CD11c+髓状细胞中的铁过载加剧了乙氨基的肝毒性
Saisai Liu1, Yohei Kanamori1, Yudai Ohta1,2
1Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Communications biology
|October 21, 2025
概括
特定免疫细胞中的铁过载会使乙氨基引起的肝损伤恶化. 降低干白素-6 (IL-6) 水平可以减轻这种肝损伤,这表明铁调节作为治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 肝病学 肝病学是一种肝病学.
- 分子生物学分子生物学
背景情况:
- 免疫反应在急性肝损伤期间批判性地调节炎症,这种炎症可以发展为肝衰竭.
- 铁在肝损伤期间调节免疫细胞功能的作用需要进一步研究.
研究的目的:
- 研究CD11c阳性 (CD11c+) 髓状细胞中铁失调对乙氨基诱导的肝损伤的影响.
- 阐明铁过载影响免疫反应和肝脏损伤的潜在机制.
主要方法:
- 利用CD11c特定的F盒和富含白的重复蛋白5 (FBXL5) 缺乏的小鼠来诱导CD11c+髓状细胞的铁过载.
- 评估肝损伤标志物,包括血清中氨酸酶水平,死亡率,中性粒细胞透和介质素-6 (IL-6) 表达.
- 研究了涉及核因子-卡帕B (NF-κB) 与IL-6促进体结合的分子机制.
- 在体内进行IL-6中和,以评估其治疗效果.
主要成果:
- 在CD11c+骨髓细胞中的FBXL5缺乏导致铁过载,加剧肝损伤,增加死亡率和增强中性粒细胞透.
- 在缺乏FBXL5的小鼠中观察到IL-6的表达升高,与肝损伤增加相关.
- 从机理上讲,铁过载促进了IL-6的产生,因为它促进了NF-κB向IL-6促进体的招募.
- 在体内IL-6中和显著减轻了乙氨基诱导的肝损伤.
结论:
- CD11c+骨髓细胞中的铁过载会通过增强的IL-6产生和炎症加剧肝损伤.
- 准铁代谢或IL-6信号传递是治疗急性肝损伤的潜在治疗策略.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249
Phase II Reactions: Acetylation Reactions
752
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
752


